DiaMedica Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $10.1 million compared to $7.7 million in the prior year period. Cash and investments decreased to $43.5 million from $59.9 million at year-end 2025, with an anticipated runway through 2027. The company provided clinical updates for its lead candidate DM199, including positive top-line results from a Phase 2 preeclampsia cohort showing significant blood pressure reductions and enrollment completion in the first cohort of a fetal growth restriction trial. Additionally, enrollment for the acute ischemic stroke Phase 2/3 ReMEDy2 trial has surpassed 85% of its target, with an interim analysis expected in early 2027. DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.